Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Genfit SA (GNFT – Research Report), with a price target of $13.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ed Arce’s rating is based on several promising developments within Genfit SA. The company is expected to have multiple significant clinical data readouts from its ACLF programs in 2025, which could potentially address the high mortality rates associated with this condition. These readouts include proof-of-concept studies for their lead ACLF program VS-01 and a new formulation of nitazoxanide, both of which aim to demonstrate improvements in patient outcomes.
Additionally, Genfit’s financial position is bolstered by a royalty financing agreement with HealthCare Royalty, providing substantial funding that extends the company’s cash runway beyond 2027. This financial stability, coupled with promising clinical milestones, supports the Buy rating as Genfit is well-positioned for future growth and advancement in its therapeutic offerings.
According to TipRanks, Arce is a 5-star analyst with an average return of 19.5% and a 49.60% success rate. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Akero Therapeutics, and Acurx Pharmaceuticals.